Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 6/20 | 0.55 |
| ▸ | RAB9A | P51151 | 6/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | GSK3B | P49841 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | STAT1 | P42224 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6360579 | 0.86 | NPC1 (0.59) | PKMKMT2ANPC1RAB9AGAA | |
| SCHEMBL28364538 | 0.82 | KMT2A (0.55) | PKMKMT2ANPC1RAB9AGAA | |
| SCHEMBL7472113 | 0.82 | KMT2A (0.55) | PKMKMT2ANPC1RAB9AGAA | |
| SCHEMBL13964532 | 0.81 | PKM (0.45) | PKMKMT2ANPC1RAB9AGAA | |
| SCHEMBL2482673 | 0.81 | GSK3B (0.56) | PKMKMT2ANPC1RAB9AGAA | |
| SCHEMBL13753327 | 0.80 | POLB (0.46) | PKMKMT2ANPC1RAB9AGAA | |
| SCHEMBL8791459 | 0.80 | HPGD (0.54) | PKMKMT2ANPC1RAB9AGAA | |
| SCHEMBL2199408 | 0.79 | PKM (0.47) | PKMKMT2ANPC1RAB9AGAA | |
| SCHEMBL2186238 | 0.79 | HPGD (0.61) | PKMKMT2ANPC1RAB9AGAA | |
| SCHEMBL7983727 | 0.79 | GAA (0.67) | PKMKMT2ANPC1RAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140024583-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-01-23 | — | — | US | disclosed |
| US-8501746-B2 | Organic compounds | XENON PHARMACEUTICALS INC. (CA) | 2013-08-06 | — | — | US | disclosed |
| WO-2007143597-A9 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-11-11 | — | — | WO | disclosed |
| EP-2029572-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| US-7576117-B1 | Cyclic amine CCR3 antagonist | TEIJIN LIMITED (JP) | 2009-08-18 | — | — | US | disclosed |
| US-7576117-B1 | Cyclic amine CCR3 antagonist | TEIJIN LIMITED (JP) | 2009-08-18 | — | — | US | disclosed |
| US-20090156615-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-06-18 | — | — | US | disclosed |
| EP-2029572-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007143597-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156615-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | PKM 1518/4885KMT2A 2098/4885NPC1 228/4885 |
| US-20140024583-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | PKM 1518/4885KMT2A 2098/4885NPC1 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.